Bilaketaren emaitzak - Ying‐Ming Jou

  • Erakusten 1 - 9 emaitzak -- 9
Findu emaitzak
  1. 1
    A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies

    A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies nork John Nemunaitis, Karen Small, Paul T. Kirschmeier, Da Zhang, Yali Zhu, Ying‐Ming Jou, Paul Statkevich, Siu‐Long Yao, Rajat Bannerji

    Argitaratua 2013
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  2. 2
    Deucravacitinib: Laboratory Parameters Across Phase 3 Plaque Psoriasis Trials

    Deucravacitinib: Laboratory Parameters Across Phase 3 Plaque Psoriasis Trials nork April W. Armstrong, Leon Kircik, Linda Stein Gold, Bruce Strober, Catarina Rodrigues Rosa De Oliveira, John Vaile, Ying‐Ming Jou, Carolin Daamen, Thomas Scharnitz, Mark Lebwohl

    Argitaratua 2025
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  3. 3
    Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias

    Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias nork Ivana Gojo, Mariola Sadowska, Alison Walker, Eric J. Feldman, Swaminathan P. Iyer, Maria R. Baer, Edward A. Sausville, Rena G. Lapidus, Da Zhang, Yali Zhu, Ying-Ming Jou, Jennifer Poon, Karen Small, Rajat Bannerji

    Argitaratua 2013
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  4. 4
    Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial

    Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial nork Meletios Α. Dimopoulos, Dominik Dytfeld, Sebastian Grosicki, Philippe Moreau, Naoki Takezako, Mitsuo Hori, Xavier Leleu, Richard LeBlanc, Kenshi Suzuki, Marc S. Raab, Paul G. Richardson, Mihaela Popa McKiver, Ying‐Ming Jou, David Yao, Prianka Das, Jesús F. San Miguel

    Argitaratua 2022
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  5. 5
    Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM

    Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM nork Andrzej Jakubowiak, Massimo Offidani, Brigitte Pegourié, Javier de la Rubia, Laurent Garderet, Kamel Laribi, Alberto Bosi, Roberto Marasca, Jacob P. Laubach, Ann Mohrbacher, Angelo Michele Carella, Anil Singhal, L. Claire Tsao, Mark Lynch, Eric Bleickardt, Ying‐Ming Jou, Michael Robbins, Antonio Palumbo

    Argitaratua 2016
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  6. 6
    Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies

    Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies nork Monica Mita, Alain C. Mita, Jennifer L. Moseley, Jennifer Poon, Karen Small, Ying-Ming Jou, Paul T. Kirschmeier, Da Zhang, Yali Zhu, Paul Statkevich, Kamelesh K Sankhala, John Sarantopoulos, James M. Cleary, Lucian R. Chirieac, Scott J. Rodig, Rajat Bannerji, Geoffrey I. Shapiro

    Argitaratua 2017
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  7. 7
    Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma

    Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma nork Meletios Α. Dimopoulos, Dominik Dytfeld, Sebastian Grosicki, Philippe Moreau, Naoki Takezako, Mitsuo Hori, Xavier Leleu, Richard LeBlanc, Kenshi Suzuki, Marc S. Raab, Paul G. Richardson, Mihaela Popa McKiver, Ying-Ming Jou, Suresh G. Shelat, Michael Robbins, Brian T. Rafferty, Jesús F. San Miguel

    Argitaratua 2018
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  8. 8
    Antitumor Activity in <i>RAS</i>-Driven Tumors by Blocking AKT and MEK

    Antitumor Activity in <i>RAS</i>-Driven Tumors by Blocking AKT and MEK nork Anthony W. Tolcher, Khurum Khan, Michael Ong, Udai Banerji, Vassiliki A. Papadimitrakopoulou, David R. Gandara, Amita Patnaik, Richard D. Baird, David Olmos, Christopher R. Garrett, Jeffrey Skolnik, Eric H. Rubin, Paul D. Smith, Pearl S. Huang, Maria Learoyd, Keith A. Shannon, Anne Morosky, Ernestina Tetteh, Ying-Ming Jou, Kyriakos P. Papadopoulos, Víctor Moreno, Brianne Kaiser, Timothy A. Yap, Yan Li, Johann S. de Bono

    Argitaratua 2014
    Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:
  9. 9
    Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study

    Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study nork Meletios Α. Dimopoulos, Sagar Lonial, Darrell White, Philippe Moreau, Katja Weisel, Jesús F. San Miguel, Ofer Shpilberg, Sebastian Grosicki, Ivan Špıčka, Adam Walter‐Croneck, Hila Magen, María‐Victoria Mateos, Andrew R. Belch, Donna Reece, Meral Beksaç, Andrew Spencer, Heather Oakervee, Robert Z. Orlowski, Masafumi Taniwaki, Christoph Röllig, Hermann Einsele, Morio Matsumoto, Ka Lung Wu, Kenneth C. Anderson, Ying‐Ming Jou, Alex Ganetsky, Anil Singhal, Paul G. Richardson

    Argitaratua 2020
    Testu osoa Testu osoa
    Artigo
    Gogokoenen artean sartu
    Gorde:

Bilaketa egiteko lanabesak: